Sexually Transmitted Diseases Market

 Market Overview:

The 7 major sexually transmitted disease markets reached a value of USD 44.0 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 100.1 Billion by 2035, exhibiting a growth rate (CAGR) of 7.75% during 2025-2035.

The sexually transmitted diseases market has been comprehensively analyzed in IMARC's new report titled "Sexually Transmitted Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Sexually transmitted diseases (STDs) refer to infections that are transmitted through sexual activity, including vaginal, anal, or oral sex. These can manifest with a wide range of symptoms, although many conditions may not cause any noticeable signs initially. Some of the common indications are genital itching, pain during urination, unusual discharge from the vagina or penis, sores, bumps, or rashes in the genital area, painful sexual intercourse, swelling or redness of the genitals, etc. Additionally, many STDs can cause flu-like symptoms, such as fever, fatigue, body aches, etc. The diagnosis of sexually transmitted diseases involves various methods to determine the presence of an infection. Healthcare professionals may use a combination of medical history assessment, physical examination, laboratory investigations, and imaging studies. A physical exam may involve inspecting the genital area for visible signs of infection. Furthermore, laboratory tests are crucial for a definitive diagnosis and may include blood, urine, and fluid samples from affected areas. In some cases, several imaging studies, like ultrasounds and X-rays, may be necessary to assess the extent of infection or complications.

The increasing cases of unprotected vaginal, anal, or oral sex with an infected partner are primarily driving the sexually transmitted diseases market. In addition to this, the rising prevalence of disease transmission through non-sexual routes, such as blood transfusions, sharing contaminated needles, from mother to child during pregnancy, childbirth, breastfeeding, etc., is acting as another significant growth-inducing factor. Moreover, the widespread demand for antiviral medications, like acyclovir, valacyclovir, famciclovir, etc., to manage outbreaks, reduce symptoms, and lower the risk of transmission is further bolstering the market growth. Apart from this, the inflating application of long-acting injectable antiretrovirals, since they provide sustained drug levels in the body while improving adherence and simplifying treatment regimens, is also creating a positive outlook for the market. Additionally, the ongoing advancements in molecular diagnostics, including the introduction of transcription-mediated amplification (TMA) and loop-mediated isothermal amplification (LAMP), which can detect and amplify the genetic material (DNA or RNA) of pathogens, thereby providing highly sensitive and specific results, are expected to drive the sexually transmitted diseases market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the sexually transmitted diseases market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for sexually transmitted diseases and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the sexually transmitted diseases market in any manner.

Recent Developments:

• In June 2024, Gilead Sciences, Inc. reported topline data from an interim analysis of its pivotal Phase 3 PURPOSE 1 trial, demonstrating that lenacapavir, the company's twice-yearly injectable HIV-1 capsid inhibitor, indicated 100% efficacy for the experimental use of HIV prevention in cisgender women.

Key Highlights:

• According to the WHO, approximately 1 million new curable sexually transmitted diseases are acquired every day around the world.
• It is estimated that 376 million new infections occur each year, with one of the four treatable sexually transmitted infections (chlamydia, gonorrhea, syphilis, and trichomoniasis).
• The CDC estimates that roughly 35,000 new HIV cases are diagnosed in the United States each year.
• The most common sexually transmitted infection in the United States is the human papillomavirus (HPV).
• At any given time, over 80% of sexually active persons are estimated to be infected, notably 42% of adults aged 18 to 59.

Drugs:

SOLOSEC (secnidazole) 2g oral granules is a prescription medication used to treat bacterial vaginosis in females aged 12 and older. SOLOSEC is used to treat Trichomoniasis, a prevalent sexually transmitted infection (STI), in people aged 12 and up. People receiving SOLOSEC for Trichomoniasis should avoid having intercourse until they and their sex partners have received the same dose and length of treatment to avoid reinfection.

Cabotegravir is an integrase strand transfer inhibitor (INSTI) developed by ViiV Healthcare to treat HIV-1 in virologically suppressed individuals. It is being tested in conjunction with injectable rilpivirine as a long-acting formulation. INSTIs reduce HIV replication by preventing viral DNA from integrating into the genetic material of human immune cells (T-cells).

Gepotidacin (GSK2140944) is the first in a new class of antibiotics, called triazaacenaphthylene topoisomerase inhibitors, developed at GSK in 2007 with a novel “dual targeting” mechanism of action (MOA) and oral formulation. Gepotidacin works by selectively interacting with two key bacterial enzymes, DNA gyrase and topoisomerase IV (type II topoisomerases), responsible for bacterial replication. The novel mechanism of action confers activity against most target pathogens resistant to established antibiotics, including fluoroquinolones.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the sexually transmitted diseases market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the sexually transmitted diseases market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current sexually transmitted diseases marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the sexually transmitted diseases market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the sexually transmitted diseases market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the sexually transmitted diseases market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of sexually transmitted diseases across the seven major markets?
• What is the number of prevalent cases (2019-2035) of sexually transmitted diseases by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of sexually transmitted diseases by gender across the seven major markets?
• What is the number of prevalent cases (2019-2035) of sexually transmitted diseases by type across the seven major markets?
• How many patients are diagnosed (2019-2035) with sexually transmitted diseases across the seven major markets?
• What is the size of the sexually transmitted diseases patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of sexually transmitted diseases?
• What will be the growth rate of patients across the seven major markets?
   

Sexually Transmitted Diseases: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for sexually transmitted diseases drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the sexually transmitted diseases market?
• What are the key regulatory events related to the sexually transmitted diseases market?
• What is the structure of clinical trial landscape by status related to the sexually transmitted diseases market?
• What is the structure of clinical trial landscape by phase related to the sexually transmitted diseases market?
• What is the structure of clinical trial landscape by route of administration related to the sexually transmitted diseases market?